On Friday, 16 October 2020, the European Union provided the following perspectives during a three hour debate on the proposed waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 co-sponsored by Eswatini, Kenya,… Continue Reading
At the October 2020 session of the World Trade Organization’s (WTO) TRIPS Council, under agenda item 1, IP measures in the context of COVID-19, the European Union read out Hungary’s detailed responses to questions posed in July 2020 (at the… Continue Reading
On Friday, 16 October 2020, members of the World Trade Organization’s (WTO) TRIPS Council held a three hour debate on the proposal (IP/C/W/669) first tabled by India and South Africa for a waiver from certain provisions of the TRIPS Agreement… Continue Reading
On Friday October 16, 2020, KEI filed a lawsuit (under the Freedom of Information Act) against the Department of Health and Human Services (HHS) and the U.S. Army regarding requests for COVID-19 research and development and procurement contracts awarding hundreds… Continue Reading
On Friday, October 9, 2020, KEI filed a lawsuit in Maryland to obtain documents from five Freedom of Information Act (FOIA) requests filed by KEI related to COVID-19. The cases involve the following issues. The complaint is attached below. FOIA… Continue Reading
Through a Freedom of Information Act (FOIA) request, Knowledge Ecology International (KEI) has obtained copies of two vaccine-related contracts entered into by the Biomedical Advanced Research and Development Authority (BARDA), one with AstraZeneca related to COVID-19 vaccines and one with… Continue Reading
Government Funding of COVID-19 Vaccines and Other Medical Technologies DATE: Tuesday, 20 October 2020 TIME: EDT 9:00 to 10:30/UTC: 13:00 to 14:30/CEST: 15:00 to 16:30 CONVENER: Knowledge Ecology International (KEI) REGISTRATION: Please contact thiru [at] keionline.org BACKGROUND: On Tuesday, 20… Continue Reading
On October 5, 2020, KEI organized a panel about government funding of COVID-19 drugs and vaccines at the Global Congress on Intellectual Property and the Public Interest. Although the full Global Congress event was postponed to the year 2021, the… Continue Reading
Regeneron Pharmaceutical recently applied for Emergency Use Authorization of its investigational COVID-19 treatment, REGN-COV2, after Donald Trump said that it cured him of COVID-19, suggesting that Regeneron expects to cash in on the treatment. Taxpayers, however, are funding 80 percent… Continue Reading
(More on KEI’s work on coronavirus here: https://www.keionline.org/coronavirus, and on Moderna, here: https://www.keionline.org/moderna) Oct 8, 2020 Moderna’s statement on intellectual property matters during the COVID-19 pandemic is very good, and should be matched by every manufacturer of a therapeutic, vaccine… Continue Reading